Latest Factor VII Stories
According to Dr Ian Roberts, Head of the World Health Organization Collaborating Centre on Injury Control at the London School of Hygiene & Tropical Medicine, the recent episode ("Big Lies, Small Lies") seriously misrepresents the scientific evidence.
KYOTO, Japan, July 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.
KING OF PRUSSIA, Pa., May 31, 2011 /PRNewswire/ -- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
MONTVILLE, N.J., and MONTREAL, April 28, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia (WFH) are announcing a three-year extension of Bayer's sponsorship agreement with WFH.
WAYNE, N.J., April 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that the U.S.
WAYNE, N.J., April 14, 2011 /PRNewswire/ -- To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia.
GENEVA, Feb. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.
- A volcanic mudflow.